Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sajith Kumar & Bhavani Shankara Bagepally. (2023) Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-14.
Read now
Read now
Michael L. Ganz, Brian Bekker Hansen, Xavier Valencia & Martin Strandberg-Larsen. (2015) Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. Journal of Medical Economics 18:5, pages 366-375.
Read now
Read now
Alexander Diamantopoulos, Maurizio Benucci, Stefano Capri, Wolfgang Berger, Neil Wintfeld, Giovanni Giuliani & Walter Ricciardi. (2012) Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. Journal of Medical Economics 15:3, pages 576-585.
Read now
Read now
Articles from other publishers (34)
S Sajith Kumar, Bhavani Shankara Bagepally & Akhil Sasidharan. (2023) Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies. Clinical Drug Investigation 43:2, pages 97-108.
Crossref
Crossref
Aliza R Karpes MatusevichLincy S LaiWenyaw ChanJ Michael SwintScott B CantorMaria E Suarez-AlmazorMaria A Lopez-Olivo. (2021) Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. Journal of Managed Care & Specialty Pharmacy 27:1, pages 73-83.
Crossref
Crossref
Ruth A. Lewis, Dyfrig Hughes, Alex J. Sutton & Clare Wilkinson. (2020) Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. PharmacoEconomics 39:1, pages 25-61.
Crossref
Crossref
Ariel Beresniak, Peter Malfertheiner, Francesco Franceschi, Francois Liebaert, Hocine Salhi & Javier P. Gisbert. (2020)
Helicobacter pylori
“Test‐and‐Treat” strategy with urea breath test: A cost‐effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain—Results of the Hp‐Breath initiative
. Helicobacter 25:4.
Crossref
Crossref
Jordan F. Hastings, Yolande E.I. O'Donnell, Dirk Fey & David R. Croucher. (2020) Applications of personalised signalling network models in precision oncology. Pharmacology & Therapeutics 212, pages 107555.
Crossref
Crossref
Aliza R. Karpes Matusevich, María E. Suarez‐Almazor, Scott B. Cantor, Lincy S. Lal, J. Michael Swint & Maria A. Lopez‐Olivo. (2020) Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors. Arthritis Care & Research 72:3, pages 343-352.
Crossref
Crossref
Evo Alemao, Maiwenn J. Al, Annelies A. Boonen, Matthew D. Stevenson, Suzanne M. M. Verstappen, Kaleb Michaud, Michael E. Weinblatt & Maureen P. M. H. Rutten-van Mölken. (2018) Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLOS ONE 13:10, pages e0205013.
Crossref
Crossref
Yongrui Bai, Yuejuan Xu & Bin Wu. (2017) Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System. Gastroenterology Research and Practice 2017, pages 1-7.
Crossref
Crossref
Saeed Ahmadiani, Shekoufeh Nikfar, Somayeh Karimi, Ahmad Reza Jamshidi, Ali Akbari-Sari & Abbas Kebriaeezadeh. (2016) Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis. Rheumatology International 36:9, pages 1291-1300.
Crossref
Crossref
Tomoyuki Takura & Kenji Miki. (2016) The future of medical reimbursement for orthopedic surgery in Japan from the viewpoint of the health economy. Journal of Orthopaedic Science 21:3, pages 273-281.
Crossref
Crossref
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Martina Biggioggero, Maurizio Benucci, Francesca Li Gobbi, Valentina Grossi, Maria Infantino, Francesca Meacci, Mariangela Manfredi, Serena Guiducci, Silvia Bellando-Randone, Marco Matucci-Cerinic, Rosario Foti, Marcella Di Gangi, Marta Mosca, Chiara Tani, Fabrizio Palmieri & Delia Goletti. (2016) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 45:5, pages 519-532.
Crossref
Crossref
Marieke Krol & Werner Brouwer. (2015) Unpaid work in health economic evaluations. Social Science & Medicine 144, pages 127-137.
Crossref
Crossref
Luca Quartuccio, Rossella di Bidino, Matteo Ruggeri, Franco Schiavon, Domenico Biasi, Silvano Adami, Leonardo Punzi, Americo Cicchetti & Salvatore de Vita. (2015) Cost‐Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis. Arthritis Care & Research 67:7, pages 947-955.
Crossref
Crossref
Jaana T. Joensuu, Saara Huoponen, Kalle J. Aaltonen, Yrjö T. Konttinen, Dan Nordström & Marja Blom. (2015) The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review. PLOS ONE 10:3, pages e0119683.
Crossref
Crossref
Stefan Scholz & Thomas Mittendorf. (2014) Modeling rheumatoid arthritis using different techniques - a review of model construction and results. Health Economics Review 4:1.
Crossref
Crossref
Jonathan Tosh, Matt Stevenson & Ron Akehurst. (2014) Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review. Current Rheumatology Reports 16:10.
Crossref
Crossref
H. G. M. van Haalen, J. L. Severens, A. Tran-Duy & A. Boonen. (2014) How to Select the Right Cost-Effectiveness Model?. PharmacoEconomics 32:5, pages 429-442.
Crossref
Crossref
Eleanor M. Heather, Katherine Payne, Mark Harrison & Deborah P. M. Symmons. (2013) Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models. PharmacoEconomics 32:2, pages 109-134.
Crossref
Crossref
Frank G. Sandmann, Margreet G. Franken, Adri Steenhoek & Marc A. Koopmanschap. (2013) Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy 112:3, pages 285-296.
Crossref
Crossref
Ebenezer Tetteh & Stephen Morris. (2013) Systematic Review of Drug Administration Costs and Implications for Biopharmaceutical Manufacturing. Applied Health Economics and Health Policy 11:5, pages 445-456.
Crossref
Crossref
Vittorio Modena, Gerolamo Bianchi & Dario Roccatello. (2013) Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?. Autoimmunity Reviews 12:8, pages 835-838.
Crossref
Crossref
Nicole W. Tsao, Nick J. Bansback, Kam Shojania & Carlo A. Marra. (2012) The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 26:5, pages 659-676.
Crossref
Crossref
Bruno Fautrel & Cécile Gaujoux-Viala. (2012) Aspects médico-économiques de la polyarthrite rhumatoïde. Bulletin de l'Académie Nationale de Médecine 196:7, pages 1295-1306.
Crossref
Crossref
Bin Wu, Baijun Dong, Yuejuan Xu, Qiang Zhang, Jinfang Shen, Huafeng Chen & Wei Xue. (2012) Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting. PLoS ONE 7:3, pages e32530.
Crossref
Crossref
Maurizio Benucci, Gianantonio Saviola, Paola Baiardi & Mariangela Manfredi. (2010) Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life. Rheumatology International 31:11, pages 1465-1469.
Crossref
Crossref
Bruno Fautrel, Suzanne M.M. Verstappen & Annelies Boonen. (2011) Economic consequences and potential benefits. Best Practice & Research Clinical Rheumatology 25:4, pages 607-624.
Crossref
Crossref
Jeffrey R. Curtis & Jasvinder A. Singh. (2011) Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical Therapeutics 33:6, pages 679-707.
Crossref
Crossref
Carlo A. Marra, Nick Bansback, Aslam H. Anis & Kamran Shojania. (2011) Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clinical Rheumatology 30:S1, pages 9-18.
Crossref
Crossref
Ariel Beresniak, Rafael Ariza-Ariza, Jose Francisco Garcia-Llorente, Antonio Ramirez-Arellano & Danielle Dupont. (2011) Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain. International Journal of Inflammation 2011, pages 1-9.
Crossref
Crossref
Hilal Maradit Kremers, Sherine E. Gabriel & Michael F. Drummond. 2011. Rheumatology. Rheumatology
23
28.e5
.
Roisin Adams, Cathal Walsh, Douglas Veale, Barry Bresnihan, Oliver FitzGerald & Michael Barry. (2010) Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis. PharmacoEconomics 28:6, pages 477-487.
Crossref
Crossref
A. Saraux, L. Gossec, P. Goupille, B. Bregman, E. Boccard, D. Dupont & A. Beresniak. (2010) Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology 49:4, pages 733-740.
Crossref
Crossref
T. A. Hallinen, E. J. O. Soini, K. Eklund & K. Puolakka. (2010) Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology 49:4, pages 767-777.
Crossref
Crossref
Sonja Merkesdal, Timm Kirchhoff, Diane Wolka, Gunter Ladinek, Adrian Kielhorn & Andrea Rubbert-Roth. (2009) Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. The European Journal of Health Economics 11:1, pages 95-104.
Crossref
Crossref